• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • socioeconomic disparities
Cirrhosis Incidence Across Socioeconomic and Demographic Groups in Sweden: A Register-Based Cohort Study and Its Global Context
Posted inClinical Updates Gastroenterology news

Cirrhosis Incidence Across Socioeconomic and Demographic Groups in Sweden: A Register-Based Cohort Study and Its Global Context

Posted by By MedXY 11/24/2025
This review synthesizes evidence on rising cirrhosis incidence in Sweden, highlighting marked socioeconomic disparities particularly in ALD- and MASLD-related cirrhosis, with broader implications across high-income countries for targeted prevention and early detection.
Read More
Evolving Landscape of Modifiable Dementia Risk Factors in Australia: Socioeconomic and Sex Disparities Over 15 Years
Posted inNeurology news Public Health

Evolving Landscape of Modifiable Dementia Risk Factors in Australia: Socioeconomic and Sex Disparities Over 15 Years

Posted by By MedXY 10/20/2025
This analysis reveals stable dementia risk fractions despite changing risk profiles over 15 years in Australia, highlighting greater modifiable risk among low-income groups and males, with depression emerging as a leading factor in mid-life, especially in women and disadvantaged populations.
Read More
Socioeconomic Disparities in Intrahepatic Cholangiocarcinoma in Sweden: Incidence, Treatment, and Survival in a Universal Healthcare Context
Posted inOncology Public Health Specialties

Socioeconomic Disparities in Intrahepatic Cholangiocarcinoma in Sweden: Incidence, Treatment, and Survival in a Universal Healthcare Context

Posted by By MedXY 08/22/2025
A nationwide Swedish study reveals significant socioeconomic disparities in intrahepatic cholangiocarcinoma incidence, treatment access, and survival despite universal healthcare coverage, underscoring persistent health inequities linked to income.
Read More
  • Neoadjuvant Chidamide plus Anthracycline–Taxane Chemotherapy Yields a 35% RCB 0–I Rate in HR+/HER2– Breast Cancer: Early Phase 2 Results from MUKDEN 05
  • Most Adolescents and Young Adults with Solid Tumours Reach Near-Normal 5-Year Survival Within Four Years — Implications for ‘Right to be Forgotten’ Policies
  • Oral KRAS G12D inhibitor GFH375 produces ORR 40.7% and DCR 96.7% in previously treated KRAS G12D pancreatic ductal adenocarcinoma: Key readouts from ESMO 2025
  • Enasidenib plus Venetoclax Shows Promising Activity in IDH2‑Mutant Relapsed/Refractory AML — ENAVEN‑AML Phase 1b/2 Results
  • Olorofim Offers a New Salvage Option for Drug‑Resistant Invasive Fungal Disease — Phase 2b Results
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation blood pressure breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials depression diabetes diet epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized controlled trial randomized trial screening sleep treatment type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in